All In Biotech

Drug Trial Radar · NCT07322003

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants With Amyotrophic Lateral Sclerosis

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Feb 1, 2026

Primary completion

Mar 2028

Study completion Mar 2029

Sponsor

Lead sponsor
PrileniaIndustry
Sponsor type
Industry
Collaborators
Ferrer Internacional S.A.
First posted
Jan 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if the drug pridopidine works to treat amyotrophic lateral sclerosis in adults. It will also help to learn about the safety of pridopidine. The main question it aims to answer is: Does pridopidine slow disease progression of ALS? Researchers will compare pridopidine to a placebo (a look-alike substance that contains no drug) to see if pridopidine works to treat ALS. Participants will: Take pridopidine or a placebo by mouth every day for 48 weeks. Afterwards, all participants will take pridopidine for another 48 weeks. Visit the clinic once every 1-3 months for checkups and tests

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • PridopidineDrug

    Pridopidine hard gelatin capsule.

  • PlaceboDrug

    Placebo hard gelatin capsule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline through Week 26 and Week 48 in the Revised ALS Functional Rating Scale (ALSFRS-R) total score adjusted for mortalityTime frame: Baseline to Week 48

Locations

56 sites in 13 countries. Site status is shown where the registry gives one.

  • Barrow Neurological Institute

    Phoenix, Arizona · Recruiting

  • California Pacific Medical Center

    San Francisco, California · Recruiting

  • University of Colorado CU Anschutz Neurology

    Aurora, Colorado · Recruiting

  • Mayo Clinic

    Jacksonville, Florida · Recruiting

  • University of South Florida

    Tampa, Florida · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • University of Kansas

    Fairway, Kansas · Recruiting

  • Johns Hopkins University

    Baltimore, Maryland · Recruiting

  • Sean M. Healey & AMG Center for ALS

    Boston, Massachusetts · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • Somnos Clinical Research

    Lincoln, Nebraska · Recruiting

  • Eleanor and Lou Gehrig ALS Center at Columbia University

    New York, New York · Recruiting

  • Neuroscience Department at LKSM at Temple University

    Philadelphia, Pennsylvania · Recruiting

  • Texas Neurology

    Dallas, Texas · Recruiting

  • Baylor College of Medicine; McNair Medical Campus

    Houston, Texas · Recruiting

  • Swedish Medical Center

    Seattle, Washington · Recruiting

  • University of Washington

    Seattle, Washington · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • University of Alberta

    Edmonton, Canada · Recruiting

  • McMaster University Medical Centre

    Hamilton, Canada · Recruiting

  • Genge Partners

    Montreal, Quebec, Canada · Recruiting

  • CHU Lille

    Lille, France · Recruiting

  • Hôpitaux Universitaires de Marseille Timone

    Marseille, France · Recruiting

  • Centre Hospitalier Universitaire de Nice

    Nice, France · Recruiting

  • Hospitalier Pitié-Salpêtrière

    Paris, France · Recruiting

  • Centre hospitalier régional universitaire de de Tours

    Tours, France · Recruiting

  • ALS outpatient department at Charité - university medicine Berlin

    Berlin, Germany · Recruiting

  • ALS Clinic Bonn University

    Bonn, Germany · Recruiting

  • Medical School Hannover, ALS Centre

    Hanover, Germany · Recruiting

  • University Hospital Jena

    Jena, Germany · Recruiting

  • Universitaetsklinikum Schleswig-Holstein, Campus Luebeck

    Lübeck, Germany · Recruiting

  • University of Ulm

    Ulm, Germany · Recruiting

  • Trinity College Dublin

    Dublin, Ireland · Recruiting

  • Hadassah Medical Center

    Jerusalem, Israel · Recruiting

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel · Recruiting

  • University of Campania "Luigi Vanvitelli"

    Caserta, Italy · Recruiting

  • Centro Clinico NEMO Fondazione Serena Onlus - ASST Niguarda Hospital

    Milan, Italy · Recruiting

  • Istituto Auxologico Italiano Ospedale San Luca

    Milan, Italy · Recruiting

  • Azienda Ospedaliero Universitaria Di Modena

    Modena, Italy · Recruiting

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.